Mp32-05 Estimating the Real-World Incidence of Urethral Complications After Prostate Cancer Treatment: A Population-Based Analysis

You have accessJournal of UrologyReconstruction: Urethral Reconstruction (Including Stricture) II (MP32)1 May 2024MP32-05 ESTIMATING THE REAL-WORLD INCIDENCE OF URETHRAL COMPLICATIONS AFTER PROSTATE CANCER TREATMENT: A POPULATION-BASED ANALYSIS Carlos I. Calvo and Keith F. Rourke Carlos I. CalvoCarlos I. Calvo and Keith F. RourkeKeith F. Rourke View All Author Informationhttps://doi.org/10.1097/01.JU.0001008816.80828.35.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: There is a paucity of literature regarding the incidence of long-term urethral complications after prostate cancer treatment. Our objective is to assess the long-term incidence of urethral complications after different treatment modalities for prostate cancer (PC). METHODS: All men with a diagnosis of PC from 2002-2021 from the Alberta Cancer Registry were included. The Discharge Abstract Data & National Ambulatory Care Reporting System were searched for different treatment modalities and urologic diagnosis/procedures. Patients were allocated into 6 different groups, radical prostatectomy (RP), radiotherapy (RT), cryotherapy (Cryo), medical treatment/observation (MT/O), RP+RT or Cryo+RT. Urethral complication was defined as development of stenosis, fistula, or having a urethral/bladder neck procedure>30 days after treatment (excluding TURP, diagnostic procedures, anti-incontinence surgery). We compared the incidence of urethral complications among different groups. RESULTS: 47,387 patients with PC diagnosis were identified with a median age of 66 years. 3,140 patients developed a urethral complication at a median follow-up of 76 months. Table 1 shows the cumulative incidence of urethral complications. On Kaplan-Meier analysis (Figure 1), urethral complication rate was different among groups (p<0.001). On multivariable Cox-regression including age (p<0.001) and stage (p=0.002), all treatment modalities (except for Cryo) were associated with development of urethral complications compared to MT/O. In particular, combined modalities such as RP+RT (HR 2.9; p<0.001) and RT+Cryo (HR 3.6; p<0.001) showed the highest risk. Complications after RP reached a plateau at 10 years whereas other modalities continued to accumulate complications over the long-term. CONCLUSIONS: Patients undergoing prostate cancer treatment are at risk developing urethral complications in the long-term regardless of treatment type. Specifically, combined modalities pose a heightened risk for developing these complications. Download PPT Source of Funding: Not applicable © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e516 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Carlos I. Calvo More articles by this author Keith F. Rourke More articles by this author Expand All Advertisement PDF downloadLoading ...